Oncolytic adenoviruses (OAds) have shown great promise in cancer therapy, but their efficacy has been greatly limited by poor tumor selectivity and highly off-target liver sequestration. Herein, we generated a novel “stealth” and tumor-targeting OAd vector, M0-TMTP1, by inserting TMTP1 (NVVRQ), a tumor-homing peptide specifically targeting metastasis, into the hypervariable region 5 of hexon. M0-TMTP1 exhibits increased transduction of tumor cells in vitro. In vivo biodistribution of M0-TMTP1 in an intraperitoneal disseminated ovarian cancer model showed significantly reduced virus load in major organs but apparent aggregation in tumors. The tumor-to-liver ratio of M0-TMTP1 was nearly 5,000-fold higher than that of control adenovirus M0. Furthermore, we armed M0-TMTP1 with trunked BID, a mitochondrial apoptosis protein, to obtain M11. Combining M11 with cisplatin (DDP) could induce an intensive antitumor effect in vitro and in vivo. Moreover, this combination therapy showed higher biosafety. Taken together, our results suggest that M11 represents a tumor-targeting, efficacious, and relatively nontoxic virotherapeutic agent, and these findings might offer renewed hope for tumor management.
Get full access to this article
View all access options for this article.
References
1.
MaCC, WangZL, XuT, et al.The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv, 2020; 40:107502.
2.
WangZ, LiuW, WangL, et al.Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia. Signal Transduct Target Ther, 2020; 5:40.
3.
HuHJ, LiangX, LiHL,. Optimization of the administration strategy for the armed oncolytic adenovirus ZD55-IL-24 in both immunocompromised and immunocompetent mouse models. Hum Gene Ther, 2021; 32:1481–1494.
4.
BakerAT, Aguirre-HernandezC, HalldenG, et al.Designer oncolytic adenovirus: coming of age. Cancers (Basel), 2018; 10:201.
5.
KleemannJ, JagerM, ValeskyE, et al.Real-world experience of talimogene laherparepvec (T-VEC) in old and oldest-old patients with melanoma: a retrospective single center study. Cancer Manag Res, 2021; 13:5699–5709.
6.
LiN, ZhouJ, WengD, et al.Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res, 2007; 13:5847–5854.
7.
ZhuR, WengD, LuS, et al.Double-dose adenovirus-mediated adjuvant gene therapy improves liver transplantation outcomes in patients with advanced hepatocellular carcinoma. Hum Gene Ther, 2018; 29:251–258.
8.
HanZ, HongZ, GaoQ, et al.A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer. Hum Gene Ther, 2012; 23:32–45.
9.
ZhouJ, GaoQ, ChenG, et al.Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability. Clin Cancer Res, 2005; 11:8431–8440.
10.
HemminkiA, KanervaA, LiuB, et al.Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res, 2003; 63:847–853.
ParkerAL, WaddingtonSN, BuckleySM, et al.Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. J Virol, 2009; 83:479–483.
13.
AlbaR, BradshawA, ParkerA, et al.Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood, 2009; 114:965–971.
14.
HajeriPB, SharmaNS, YamamotoM. Oncolytic adenoviruses: strategies for improved targeting and specificity. Cancers (Basel), 2020; 12:1504.
15.
YangW, LuoD, WangS, et al.TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin Cancer Res, 2008; 14:5494–5502.
16.
ZhouY, JiangG, WangW, et al.A novel near-infrared fluorescent probe TMTP1-PEG4-ICG for in vivo tumor imaging. Bioconjug Chem, 2018; 29:4119–4126.
17.
LiF, ChengT, DongQ, et al.Evaluation of (99m)Tc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT. Nucl Med Biol, 2015; 42:256–262.
18.
MaX, XiL, LuoD, et al.Anti-tumor effects of the peptide TMTP1-GG-D(KLAKLAK)(2) on highly metastatic cancers. PLoS One, 2012; 7:e42685.
19.
LiuR, XiL, LuoD, et al.Enhanced targeted anticancer effects and inhibition of tumor metastasis by the TMTP1 compound peptide TMTP1-TAT-NBD. J Control Release, 2012; 161:893–902.
20.
YouZ, FischerDC, TongX, et al.Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression. Cancer Gene Ther, 2001; 8:168–175.
21.
DaiY, ZhaoXJ, LiF, et al.Truncated bid regulates cisplatin response via activation of mitochondrial apoptosis pathway in ovarian cancer. Hum Gene Ther, 2020; 31:325–338.
22.
AsselinE, MillsG, TsangB. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res, 2001; 61:1862–1868.
23.
GaoQ, ZhouJ, HuangX, et al.Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus. Mol Ther, 2006; 13:928–937.
24.
HuangX, ZhuangL, CaoY, et al.Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration. Mol Cancer Ther, 2008; 7:1624–1632.
25.
Ullman-CullereMH, FoltzCJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci, 1999; 49:319–323.
26.
LiuD, ZhangXX, LiMC, et al.C/EBPbeta enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation. Nat Commun, 2018; 9:1739.
27.
WuH, HanT, BelousovaN, et al.Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol, 2005; 79:3382–3390.
28.
McConnellMJ, DanthinneX, ImperialeMJ. Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol, 2006; 80:5361–5370.
29.
Ni ChonghaileT, SarosiekKA, VoTT, RyanJA, et al.Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science, 2011; 334:1129–1133.
30.
HarringtonK, FreemanDJ, KellyB, et al.Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov, 2019; 18:689–706.
PrillJM, EspenlaubS, SamenU, et al.Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. Mol Ther, 2011; 19:83–92.
33.
KhareR, MaySM, VetriniF, et al.Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. Mol Ther, 2011; 19:1254–1262.
34.
ZhangZ, KrimmelJ, ZhangZ, et al.Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model. Hum Gene Ther, 2011; 22:1137–1142.
35.
ParkerAL, WaddingtonSN, NicolCG, et al.Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood, 2006; 108:2554–2561.
36.
AtodaH, IshikawaM, MizunoH, et al.Coagulation factor X-binding protein from Deinagkistrodon acutus venom is a Gla domain-binding protein. Biochemistry, 1998; 37:17361–17370.
37.
NguyenTV, Anguiano-ZarateSS, MatchettWE, et al.Retargeted and detargeted adenovirus for gene delivery to the muscle. Virology, 2018; 514:118–123.
38.
NicklinSA, WhiteSJ, WatkinsSJ, et al.Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation, 2000; 102:231–237.
39.
StepanenkoAA, ChekhoninVP. Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: focus on fiber chimerism and mosaicism, hexon and pIX. Virus Res, 2018; 257:40–51.
40.
VigneE, MahfouzI, DedieuJF, et al.RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol, 1999; 73:5156–5161.
41.
Uusi-KerttulaH, DaviesJA, ThompsonJM, et al.Ad5NULL-A20: a tropism-modified, alphavbeta6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clin Cancer Res, 2018; 24:4215–4224.
42.
WangD, LiW, ZhangH, et al.A targeting peptide improves adenovirus-mediated transduction of a glioblastoma cell line. Oncol Rep, 2014; 31:2093–2098.
43.
DengJ. How to unleash mitochondrial apoptotic blockades to kill cancers?. Acta Pharm Sin B, 2017; 7:18–26.
44.
SarosiekKA, Ni ChonghaileT, LetaiA. Mitochondria: gatekeepers of response to chemotherapy. Trends Cell Biol, 2013; 23:612–619.
45.
ChipukJE, MoldoveanuT, LlambiF, et al.The BCL-2 family reunion. Mol Cell, 2010; 37:299–310.
46.
StallwoodY, FisherK, GallimoreP, et al.Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients. Gene Ther, 2000; 7:637–643.
47.
BlackwellJ, LiH, Gomez-NavarroJ, et al.Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid. Hum Gene Ther, 2000; 11:1657–1669.
48.
HemminkiA, WangM, DesmondR, et al.Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum Gene Ther, 2002; 13:1505–1514.
49.
MaJ, DuffyM, DengL, et al.Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo. PLoS Pathogens, 2015; 11:e1004673.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
